51.94
3.42%
1.72
Dopo l'orario di chiusura:
51.94
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CYTK Giù?
Forum
Previsione
Frazionamento azionario
Cytokinetics Inc Borsa (CYTK) Ultime notizie
H.C. Wainwright keeps Buy rating on Cytokinetics shares, citing promising data on aficamten and omecamtiv - Investing.com Canada
Cytokinetics' (CYTK) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024 - Yahoo Finance
Principal Financial Group Inc. Sells 120,497 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024 - Marketscreener.com
Significant Portfolio Addition: T. Rowe Price Investment Managem - GuruFocus.com
Insider Sale at Cytokinetics Inc (CYTK): EVP Research & Developm - GuruFocus.com
Cytokinetics: On The Cusp Of Commercialization (NASDAQ:CYTK) - Seeking Alpha
Cytokinetics EVP sells $370,880 in stock By Investing.com - Investing.com Nigeria
Cytokinetics EVP sells $370,880 in stock - Investing.com
Cytokinetics' SWOT analysis: cardiac drug maker's stock poised for growth - Investing.com
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives $83.67 Average Price Target from Brokerages - MarketBeat
FMR LLC Bolsters Stake in Cytokinetics Inc - GuruFocus.com
Cytokinetics to Present at Jefferies London Healthcare Conference 2024 | CYTK Stock News - StockTitan
Lisanti Capital Growth LLC Sells 26,800 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics Launches Phase 1 Trial for Novel Muscle Function Drug CK-089 | CYTK Stock News - StockTitan
HC Wainwright Forecasts Reduced Earnings for Cytokinetics - MarketBeat
Cytokinetics, Incorporated Announces Initiation of Phase 1 Clinical Study of CK-4015089 - Marketscreener.com
Van ECK Associates Corp Has $3.80 Million Stock Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics started at outperform by RBC, valuation cited - MSN
Eyeing drug launch in 2025, Cytokinetics rolls out HCM awareness campaign - MM+M Online
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Cytokinetics (NASDAQ:CYTK) Now Covered by Analysts at Royal Bank of Canada - MarketBeat
Cytokinetics, Incorporated (NASDAQ:CYTK) Q3 2024 Earnings Call Transcript - Insider Monkey
Cytokinetics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Cytokinetics: Q3 Earnings Snapshot - AOL
Cytokinetics director resigns, board reduced to eight By Investing.com - Investing.com UK
Cytokinetics (NASDAQ:CYTK) Posts Earnings Results, Misses Estimates By $0.09 EPS - MarketBeat
Cytokinetics Inc (CYTK) Q3 2024 Earnings Call Highlights: Strate - GuruFocus.com
Cytokinetics Inc (CYTK) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance
Cytokinetics Inc earnings missed by $0.13, revenue fell short of estimates - Investing.com Canada
Cytokinetics (CYTK) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Cytokinetics Reports Third Quarter 2024 Financial Results - The Manila Times
International Assets Investment Management LLC Takes Position in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics Announces Six Upcoming Presentations at the American Heart Association Scientific Sessions 2024 - The Manila Times
Cytokinetics Announces Six Upcoming Presentations at the American Heart Association Scientific ... - NRToday.com
Earnings To Watch: Cytokinetics Inc (CYTK) Reports Q3 2024 Resul - GuruFocus.com
Earnings To Watch: Cytokinetics Inc (CYTK) Reports Q3 2024 Result - Yahoo Finance
AlphaCentric Advisors LLC Takes Position in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Vanguard Group Inc's Strategic Acquisition of Cytokinetics Inc S - GuruFocus.com
Robert I. Blum Sells 5,000 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock - MarketBeat
Cytokinetics CEO Robert Blum sells $258,150 in stock - Investing.com
Cytokinetics CEO Robert Blum sells $258,150 in stock By Investing.com - Investing.com Australia
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - XM
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Cytokinetics director Wendall Wierenga sells shares worth $232,617 By Investing.com - Investing.com South Africa
abrdn plc Trims Stock Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics EVP Malik Fady Ibraham sells $378,930 in stock By Investing.com - Investing.com Australia
Cytokinetics director Wendall Wierenga sells shares worth $232,617 - Investing.com India
Cytokinetics EVP Malik Fady Ibraham sells $378,930 in stock - Investing.com
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):